Stock ONWARD MEDICAL (NL0015000HT4)
Sector : Medical Equipment & Services – Indices : BEL ALL-SHARE, AEX ALL-SHARE
Last update : 24/04/2026 at 17:37:22 – Source: Euronext
Market summary
As of 24/04/2026, stock ONWARD MEDICAL trades at 2,92 € , with a change of -0,85 % , and a market cap of 203 M€. Reference period : Q3 2025.
Price and moving averages
Technical analysis ONWARD MEDICAL
| 50-day moving average3,59 €-18.80 % (below) | Pivot2,92 € |
|---|---|
| Support level2,82 €-3.26 % | Resistance level3,78 €+29.67 % |
| 1-month volatility13,78 % | Annualised volatility47,75 % |
| RSI (14d)36 Neutral | Stochastic signal (14d)Neutre |
| ATR (14d)0,16 Low volatility | CMF (21d)-0,38 Moderate selling pressure |
| Bollinger bands (20d) Neutral | OBV (21d) Neutral (OBV stable) |
Recent news — ONWARD MEDICAL
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this operation are now admit…
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this fundraising are now adm…
ONWARD Medical has announced a capital increase through a private placement targeting institutional investors, aiming to raise approximately €40 milli…
The biotech specializing in mobility restoration after spinal cord injury shows a dramatic acceleration in its U.S. sales, with 117 ARC-EX systems sol…
Latest earnings
| Annuels Q3 2025 | |
|---|---|
| Revenue | EUR 1,7 million |
Guidance
| Management commentary | Anticipe le premier patient enrôlé dans l'étude pivot Empower BP avant la fin de l'année. S'attend à accélération de la croissance en 2026 suite à la CE Mark et à la clearance FDA pour usage à domicile. Net proceeds from > EUR 50 million equity raise expected to provide cash runway into Q1 2027, assuming no draw down of the debt facility. |
|---|
Identified risks and opportunities
Opportunities
- FDA clearance for home use expands US market opportunity
- CE Mark enables commercialization in EU and facilitates entry to UK and Switzerland
- Strong clinical publications (Nature, Nature Medicine, Neurology: Clinical Practice) bolster evidence base
- IDE approval for ARC-IM enables initiation of Empower BP pivotal study
Risks
- retards dans les autorisations réglementaires
- variations de la demande commerciale
- concurrence technologique et concurrentielle
- incertitudes liées aux études cliniques et résultats futurs
Analyses on ONWARD MEDICAL stock
No analysis has been published on this stock yet.
Frequently asked questions about ONWARD MEDICAL stock
What does the recent price action of ONWARD MEDICAL stock show?
ONWARD MEDICAL stock is currently trading around 2,92 €, down 0,85% and up +0,01% over one week.
Is ONWARD MEDICAL stock in a support or resistance zone?
Technical levels help place the stock. Support: 2,82 €. Resistance: 3,78 €.
How should the current volatility of ONWARD MEDICAL stock be interpreted?
Volatility is around 47,75%.
